Xeomin (Botulinum neurotoxin type A) is in clinical development for the treatment of adults with lower limb and/or upper limb spasticity. Spasticity is a long-term symptom described as a pathological increase in muscle tension (hypertonicity) resulting from damages to the brain, spinal cord, or motor nerves associated with conditions such as stroke, traumatic brain injury (TBI), cerebral palsy, multiple sclerosis, etc. The hypertonicity in muscles leads to permanent hardening and stiffening. While there are treatments available for treating upper limb spasticity, there are limited options for spasticity affecting the lower limbs. Xeomin could provide an additional treatment option for lower limb spasticity and/or upper limb spasticity.
Xeomin (Botulinum neurotoxin type A) for lower limb and/or upper limb spasticity
Xeomin (Botulinum neurotoxin type A) is in clinical development for the treatment of adults with lower limb and/or upper limb spasticity. Spasticity is a long-term symptom described as a pathological increase in muscle tension (hypertonicity) resulting from damages to the brain, spinal cord, or motor nerves associated with conditions such as stroke, traumatic brain injury (TBI), cerebral palsy, multiple sclerosis, etc.